Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC

Recruiting now · Phase 2

Conditions studied: Triple-negative Breast Cancer

In brief

We plan to explore the efficacy and safety of albumin-bound paclitaxel+carboplatin+Camrelizumab in neoadjuvant therapy for early TNBC patients, optimize the administration method and drug combination therapy.

Key facts

Study ID: NCT06817525
Run by: Henan Cancer Hospital
People needed: 64
Starts: 2024-11-06
Expected to finish: 2026-05-31
Last updated by the study team: 2025-12-05

Who can join

Age: 18 and older, up to 65. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

Age: 18-65 years old;
Clinically and pathologically confirmed cT2- cT4d, or cT1c with axillary lymph node metastasis;
Three negative type and invasive breast cancer confirmed by histopathology;
Three negative breast cancer is defined as:
ER and PR negative (IHC nuclear staining<10%)
Her-2 negative (IHC 0, 1+without FISH, or IHC 2+without FISH amplification)
Clinically measurable lesions:
Measurable lesions displayed by ultrasound, mammography, or MR (optional) within one month prior to screening;
Organ and bone marrow function tests within 2 weeks before chemotherapy indicate no contraindications for chemotherapy:
Absolute value of neutrophil count ≥ 2.0 × 109/L
Hemoglobin ≥ 100g/L
Platelet count ≥ 100 × 109/L
Total bilirubin<1.5 ULN (upper limit of normal)
Creatinine<1.5 × ULN
AST/ALT < 1.5×ULN；
Thyroid stimulating hormone (TSH) ≤ upper limit of normal (ULN); If there are abnormalities, T3 and T4 levels should be examined. If T3 and T4 levels are normal, they can be selected
Prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 ULN, while meeting international standards Normalization ratio (INR) ≤ 1.5 ULN (not receiving anticoagulant therapy);
Cardiac ultrasound EF value ≥ 55%;
Women of childbearing age who tested negative for serum pregnancy test 14 days before randomization;
ECOG score ≤ 1 point;
Voluntary signing of informed consent

You may not qualify if…

There is evidence of metastatic breast cancer (in order to exclude metastatic breast cancer, chest and abdomen CT and bone scanning should be performed at any time point before diagnosis and randomization; PET/CT scanning can be used as an alternative imaging inspection method);
Have Received chemotherapy, endocrine therapy, targeted therapy, radiation therapy, etc. for this disease;
The patient has a second primary malignant tumor, in addition to: fully treated skin cancer;
Received treatment with anti-PD-1, anti-PDL1, anti-PD-L2 drugs, or other immunotherapy;
Diagnosed with immunodeficiency or autoimmune diseases;
Severe lung or heart disease;
Hepatitis B and C are in active phase;
History of organ transplantation or bone marrow transplantation;
Pregnant or lactating women;
Due to serious and uncontrollable medical conditions, researchers believe there are contraindications to chemotherapy;
Screening for clinically significant bleeding symptoms or significant bleeding tendencies within the previous month;
Screening for arteriovenous thrombosis events such as deep vein thrombosis and pulmonary embolism that occurred within the previous 3 months.

Where it is running

Henan cancer hospital — Zhengzhou, Henan, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.